ARTICLE | Clinical News
Elagolix: Phase IIb started
April 1, 2013 7:00 AM UTC
Neurocrine began a double-blind, placebo-controlled Phase IIb trial to evaluate elagolix alone and in combination with estradiol/norethindrone acetate therapy for 6 months in about 280 female patients...